주식회사 유틸렉스

Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies.

Vinay DS, Kwon BS.

Abstract :

4-1BB (CD137) is an important T-cell stimulating molecule. The 4-1BB mAb or its variants have shown remarkable therapeutic activity against autoimmunity, viral infections, and cancer. Antibodies to 4-1BB have recently entered clinical trials for the treatment of cancer with favorable toxicity profile. In this article, we present a review documenting the efficacy and pitfalls of 4-1BB therapy.

AREAS COVERED:

An extensive literature search has been made on 4-1BB, spanning two decades, and a comprehensive report is presented here highlighting the origins, biological effects, therapeutic potential, and mechanistic basis of targeting 4-1BB as well as the side effects associated with such therapy.

EXPERT OPINION:

Research so far indicates that 4-1BB is highly protective against various pathological conditions including cancer. However, a few important side effects of 4-1BB therapy such as liver toxicity, thrombocytopenia, anemia, and suppressive effects on certain immune competent cells should be taken into consideration before it is used for human therapy.

KEYWORDS:

4-1BB; T cells; autoimmune disease; cancer; therapy

Expert Opin Ther Targets. 2016;20(3):361-73. doi: 10.1517/14728222.2016.1091448. Epub 2015 Oct 1.